Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical hodgkin lymphoma

American Journal of Surgical Pathology

Volumn 37, Issue 8, 2013, Pages 1242-1251

  Koh, Young Wha ^a   Park, Chansik ^a   Yoon, Dok Hyun ^a   Suh, Cheolwon ^a   Huh, Jooryung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bcl 2; COX 2; Hodgkin lymphoma; microvessel density; prognosis; VEGF

Indexed keywords

CD31 ANTIGEN; CYCLOOXYGENASE 2; PROTEIN BCL 2; PTGS2 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CAPILLARY; CHEMISTRY; CHI SQUARE DISTRIBUTION; CHILD; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD31; BIOPSY; CAPILLARIES; CHI-SQUARE DISTRIBUTION; CHILD; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84880546492     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31828b6ad3     Document Type: Article

References (51)

1. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J. 2009;15:161-163
2. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752
3. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362: 875-885
4. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 2012;88:292-305
5. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein- Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol. 2009;27:3815-3821
6. Koh YW, Yoon DH, Suh C, et al. Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea. Ann Hematol. 2012;91:1403-1412
7. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000;60:5040-5044
8. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596
9. Langman MJ, Cheng KK, Gilman EA, et al. Effect of antiinflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ. 2000;320:1642-1646
10. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064-4068
11. Nozoe T, Ezaki T, Kabashima A, et al. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg. 2005;189:110-115
12. Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol. 2004;35:488-495
13. Folkman J,Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288
14. Ferrara N. VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000;11:617-624
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65
16. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434
17. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78:1379-1384
18. Uchida S, Shimada Y, Watanabe G, et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer. 1998;77:1704-1709
19. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60:23-32
20. Martinez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: A comparative study at the mRNA and protein level. Anticancer Res. 2007;27:219-222
21. Leahy DT, Mulcahy HE, O'Donoghue DP, et al. Bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology. 1999;35:360-367
22. Bai M, Papoudou-Bai A, Horianopoulos N, et al. Expression of Bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol. 2007;38:103-113
23. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893
24. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001;7:3410-3415
25. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409
26. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: A morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19:894-900
27. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683
28. Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma. 2006;47:223-230
29. Mestre F, Gutierrez A, Ramos R, et al. Expression of COX-2 on Reed- Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood. 2012;119:6072-6079
30. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716
31. Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF- 1alpha in Hodgkin lymphoma. Pathol Res Pract. 2009;205:11-20
32. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362-366
33. Basu GD, Pathangey LB, Tinder TL, et al. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2004;2:632-642
34. Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007;14:2738-2747
35. Hammes LS, Tekmal RR, Naud P, et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol. 2008;110:445-451
36. Zhang XH, Huang DP, Guo GL, et al. Coexpression of VEGF-C and COX-2 andits association with lymphangiogenesis in human breast cancer. BMC Cancer. 2008;8:4
37. Huh J, Cho K, Heo DS, et al. Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. Am J Hematol. 1999;60: 205-214
38. Miller R, Siegmund D. Maximally selected x2 statistics. Biometrics. 1982;38:1011-1016
39. Halpern J. Maximally selected x2 statistics for small samples. Biometrics. 1982;38:1017-1023
40. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589-1594
41. Ohno S, Ohno Y, Suzuki N, et al. Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res. 2007;27:3765-3770
42. Ohsawa M, Fukushima H, Ikura Y, et al. Expression of cyclooxygenase- 2 in Hodgkin's lymphoma: Its role in cell proliferation and angiogenesis. Leuk Lymphoma. 2006;47:1863-1871
43. Yahalom J. Favorable early-stage Hodgkin lymphoma. J Natl Compr Canc Netw. 2006;4:233-240
44. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21:2645-2650
45. Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report. J Steroid Biochem Mol Biol. 2003;86:443-447
46. Fujita J, Mestre JR, Zeldis JB, et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res. 2001;7:3349-3355
47. Boll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010;148:480-482
48. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191
49. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342
50. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A populationbased study. J Clin Oncol. 2005;23:7604-7613
51. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population- based study. Blood. 2005;106:2444-2451